| NB7 |
Growth inhibition assay |
|
|
Inhibition of human NB7 cell growth in a cell viability assay, IC50=2.27473μM |
SANGER |
| LB2241-RCC |
Growth inhibition assay |
|
|
Inhibition of human LB2241-RCC cell growth in a cell viability assay, IC50=6.57739μM |
SANGER |
| NCI-H1299 |
Growth inhibition assay |
|
|
Inhibition of human NCI-H1299 cell growth in a cell viability assay, IC50=13.2019μM |
SANGER |
| BV-173 |
Growth inhibition assay |
|
|
Inhibition of human BV-173 cell growth in a cell viability assay, IC50=14.0505μM |
SANGER |
| HPAF-II |
Growth inhibition assay |
|
|
Inhibition of human HPAF-II cell growth in a cell viability assay, IC50=14.5873μM |
SANGER |
| RS4-11 |
Growth inhibition assay |
|
|
Inhibition of human RS4-11 cell growth in a cell viability assay, IC50=16.6795μM |
SANGER |
| EW-1 |
Growth inhibition assay |
|
|
Inhibition of human EW-1 cell growth in a cell viability assay, IC50=17.1883μM |
SANGER |
| NCI-H1581 |
Growth inhibition assay |
|
|
Inhibition of human NCI-H1581 cell growth in a cell viability assay, IC50=17.2588μM |
SANGER |
| SK-PN-DW |
Growth inhibition assay |
|
|
Inhibition of human SK-PN-DW cell growth in a cell viability assay, IC50=17.9485μM |
SANGER |
| KP-4 |
Growth inhibition assay |
|
|
Inhibition of human KP-4 cell growth in a cell viability assay, IC50=19.1087μM |
SANGER |
| DU-145 |
Growth inhibition assay |
|
|
Inhibition of human DU-145 cell growth in a cell viability assay, IC50=19.8748μM |
SANGER |
| ACHN |
Growth inhibition assay |
|
|
Inhibition of human ACHN cell growth in a cell viability assay, IC50=20.6213μM |
SANGER |
| A172 |
Growth inhibition assay |
|
|
Inhibition of human A172 cell growth in a cell viability assay, IC50=21.263μM |
SANGER |
| HuO-3N1 |
Growth inhibition assay |
|
|
Inhibition of human HuO-3N1 cell growth in a cell viability assay, IC50=21.4318μM |
SANGER |
| QIMR-WIL |
Growth inhibition assay |
|
|
Inhibition of human QIMR-WIL cell growth in a cell viability assay, IC50=22.3274μM |
SANGER |
| NCI-H1650 |
Growth inhibition assay |
|
|
Inhibition of human NCI-H1650 cell growth in a cell viability assay, IC50=22.7873μM |
SANGER |
| SW1088 |
Growth inhibition assay |
|
|
Inhibition of human SW1088 cell growth in a cell viability assay, IC50=23.1641μM |
SANGER |
| Mewo |
Growth inhibition assay |
|
|
Inhibition of human Mewo cell growth in a cell viability assay, IC50=23.3997μM |
SANGER |
| NCI-H1355 |
Growth inhibition assay |
|
|
Inhibition of human NCI-H1355 cell growth in a cell viability assay, IC50=24.6365μM |
SANGER |
| SK-LU-1 |
Growth inhibition assay |
|
|
Inhibition of human SK-LU-1 cell growth in a cell viability assay, IC50=27.058μM |
SANGER |
| KYSE-70 |
Growth inhibition assay |
|
|
Inhibition of human KYSE-70 cell growth in a cell viability assay, IC50=27.125μM |
SANGER |
| KP-N-YS |
Growth inhibition assay |
|
|
Inhibition of human KP-N-YS cell growth in a cell viability assay, IC50=27.5706μM |
SANGER |
| HTC-C3 |
Growth inhibition assay |
|
|
Inhibition of human HTC-C3 cell growth in a cell viability assay, IC50=27.7345μM |
SANGER |
| NB17 |
Growth inhibition assay |
|
|
Inhibition of human NB17 cell growth in a cell viability assay, IC50=27.9113μM |
SANGER |
| GOTO |
Growth inhibition assay |
|
|
Inhibition of human GOTO cell growth in a cell viability assay, IC50=27.9415μM |
SANGER |
| BEN |
Growth inhibition assay |
|
|
Inhibition of human BEN cell growth in a cell viability assay, IC50=29.865μM |
SANGER |
| HMV-II |
Growth inhibition assay |
|
|
Inhibition of human HMV-II cell growth in a cell viability assay, IC50=30.1553μM |
SANGER |
| SF295 |
Growth inhibition assay |
|
|
Inhibition of human SF295 cell growth in a cell viability assay, IC50=32.156μM |
SANGER |
| MPP-89 |
Growth inhibition assay |
|
|
Inhibition of human MPP-89 cell growth in a cell viability assay, IC50=33.5199μM |
SANGER |
| LCLC-103H |
Growth inhibition assay |
|
|
Inhibition of human LCLC-103H cell growth in a cell viability assay, IC50=34.2223μM |
SANGER |
| MN-60 |
Growth inhibition assay |
|
|
Inhibition of human MN-60 cell growth in a cell viability assay, IC50=36.0139μM |
SANGER |
| BB65-RCC |
Growth inhibition assay |
|
|
Inhibition of human BB65-RCC cell growth in a cell viability assay, IC50=36.1528μM |
SANGER |
| BHY |
Growth inhibition assay |
|
|
Inhibition of human BHY cell growth in a cell viability assay, IC50=36.9645μM |
SANGER |
| SK-MEL-3 |
Growth inhibition assay |
|
|
Inhibition of human SK-MEL-3 cell growth in a cell viability assay, IC50=37.7324μM |
SANGER |
| NY |
Growth inhibition assay |
|
|
Inhibition of human NY cell growth in a cell viability assay, IC50=37.7592μM |
SANGER |
| CAL-72 |
Growth inhibition assay |
|
|
Inhibition of human CAL-72 cell growth in a cell viability assay, IC50=37.9289μM |
SANGER |
| ES3 |
Growth inhibition assay |
|
|
Inhibition of human ES3 cell growth in a cell viability assay, IC50=38.1949μM |
SANGER |
| NBsusSR |
Growth inhibition assay |
|
|
Inhibition of human NBsusSR cell growth in a cell viability assay, IC50=39.3132μM |
SANGER |
| NB10 |
Growth inhibition assay |
|
|
Inhibition of human NB10 cell growth in a cell viability assay, IC50=40.1731μM |
SANGER |
| ChaGo-K-1 |
Growth inhibition assay |
|
|
Inhibition of human ChaGo-K-1 cell growth in a cell viability assay, IC50=41.1576μM |
SANGER |
| KYSE-450 |
Growth inhibition assay |
|
|
Inhibition of human KYSE-450 cell growth in a cell viability assay, IC50=41.4514μM |
SANGER |
| SK-MEL-1 |
Growth inhibition assay |
|
|
Inhibition of human SK-MEL-1 cell growth in a cell viability assay, IC50=41.9927μM |
SANGER |
| PC-3 |
Growth inhibition assay |
|
|
Inhibition of human PC-3 cell growth in a cell viability assay, IC50=42.2752μM |
SANGER |
| KARPAS-299 |
Growth inhibition assay |
|
|
Inhibition of human KARPAS-299 cell growth in a cell viability assay, IC50=44.5948μM |
SANGER |
| DBTRG-05MG |
Growth inhibition assay |
|
|
Inhibition of human DBTRG-05MG cell growth in a cell viability assay, IC50=44.6546μM |
SANGER |
| HCC1806 |
Growth inhibition assay |
|
|
Inhibition of human HCC1806 cell growth in a cell viability assay, IC50=45.2169μM |
SANGER |
| NCI-H2009 |
Growth inhibition assay |
|
|
Inhibition of human NCI-H2009 cell growth in a cell viability assay, IC50=45.2843μM |
SANGER |
| HCC2157 |
Growth inhibition assay |
|
|
Inhibition of human HCC2157 cell growth in a cell viability assay, IC50=45.7976μM |
SANGER |
| EM-2 |
Growth inhibition assay |
|
|
Inhibition of human EM-2 cell growth in a cell viability assay, IC50=47.4011μM |
SANGER |
| DOK |
Growth inhibition assay |
|
|
Inhibition of human DOK cell growth in a cell viability assay, IC50=48.3877μM |
SANGER |
| HepG2 |
Function assay |
|
|
Inhibition of cJun phosphorylation in HepG2 cell line, Ki=0.004μM |
16759099 |
| HepG2 |
Function assay |
|
|
Inhibition of cJun phosphorylation in HepG2 cell line, EC50=0.92μM |
16759099 |